Golotimod (TFA)

Golotimod (TFA)

• CAS Number: 2828433-07-2
• UNSPSC Description: Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].
• Target Antigen: Bacterial; STAT
• Type: Reference compound
• Related Pathways: Anti-infection;JAK/STAT Signaling;Stem Cell/Wnt
• Applications: COVID-19-anti-virus
• Field of Research: Infection; Inflammation/Immunology; Cancer
• Assay Protocol: https://www.medchemexpress.com/golotimod-tfa.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2.OC(C(F)(F)F)=O
• Molecular Weight: 447.36
• References & Citations: [1]Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6.|[2]Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92.|[3]Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60.
• Shipping Conditions: Room temperature
• Clinical Information: Phase 2